MISSION・VISION
MISSION
Contributing to the health and medical care
of people around the world through innovation
in biopharmaceutical manufacturing.
VISION
Aiming to be a CDMO, which provides values globally,
by realizing “Advanced Biomanufacturing Factory”
integrated innovative technologies such as continuous manufacturing.
We will create value both domestically and overseas
by building an Advanced Biomanufacturing Factory.
Renzoku Biologics’ Founding Vision
Bringing innovation to antibody drug manufacturing through advanced technology
Evolution of the Biopharmaceutical Industry and Manufacturing Technologies
The dawn of the biopharmaceutical industry dates back to 1978, when Genentech licensed the production of human insulin using recombinant DNA technology to Lilly.
Looking back, it can be said that from its very inception, the biopharmaceutical industry has been built upon technologies for manufacturing useful biological compounds.
Over the subsequent 40 years, new biopharmaceuticals, such as antibodies and cell and gene therapies, have continued to emerge one after another. However, regardless of the modality, “manufacturing” bears a crucial role and responsibility throughout the entire process of transforming a drug candidate into a finished product and delivering it to patients.
We believe that to fulfill this role and responsibility, “manufacturing” must continuously evolve in terms of speed, quality, and cost, and that continuous innovation in manufacturing technology is essential.
Vulnerability of Domestic Production Capacity Revealed by the COVID-19 Pandemic
Through the vaccine supply concerns during the COVID-19 pandemic, we acutely felt the lack of domestic production capacity for biopharmaceuticals.
However, we believe that achieving a stable supply is not the only challenge; without strengthening our ability to “produce” biopharmaceuticals, it will be difficult to revitalize Japan’s drug discovery capabilities and cultivate the pharmaceutical industry as a core industry of our nation.
Establishment of Renzoku Biologics and Our Goal
Driven by this awareness, we established Renzoku Biologics Inc. in 2023 with the goal of becoming a CDMO that delivers value both domestically and globally as a Center of Excellence (CoE) that brings innovation to antibody drug manufacturing by realizing an “Advanced Biomanufacturing Factory” through the integration of advanced manufacturing technologies, including continuous production.
Through a comprehensive range of contract services—from the building CMC development strategies to the manufacturing of investigational and commercial drugs—Renzoku Biologics acts as an expert in antibody drug production, assisting our clients with antibody drug development, adoption of advanced manufacturing technologies, and production capacity management.
Through these services, our aspiration is to deliver the antibody drugs needed by patients worldwide to them as quickly as possible, with high quality and at low manufacturing costs.
Challenges of Being a “New CDMO”
Since our founding, we have aimed to be a “new CDMO” that goes beyond mere contract manufacturing to fundamentally support our clients’ development efforts by leveraging cutting-edge technologies.
Our business model is centered on providing our clients with unprecedented value by integrating advanced biomanufacturing technologies into the entire pharmaceutical development process, from upstream to downstream.
The diagram below visually illustrates the overall structure of our business model, the core technologies that underpin it, and the value we deliver to our clients.
Hitoshi Kuboniwa, Chief Executive Officer
Company Overview
| Company Name (Trade Name) | Renzoku Biologics Inc. |
| Founded | August 22, 2023 |
| Representative | Dr. Hitoshi Kuboniwa, Chief Executive Officer |
| Capital | 100 million yen |
| Major Shareholder | SIIX Corporation (98.9% stake) https://www.siix.co.jp/ |
| Number of Employees | 33 (as of March 2026), including executives and advisors |
| Location | 【Headquarters】 Marunouchi Trust Tower Main 20F, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan 【Mizonokuchi R&D】 |
| Business fields | Therapeutic antibodies CDMO （Contract Development Manufacturing Organization） |
【Headquarters】
【Mizonokuchi R&D】
Executive Profiles
| President and Representative Director, Chief Executive Officer (CEO), Chief Technology Officer (CTO), and Chief Business Development Officer (CBDO) |
Hitoshi Kuboniwa | Dr. Kuboniwa worked at Chugai Pharmaceutical Co., Ltd. for 37 years. He engaged in discovery research and business development, and subsequently served as Director of the Formulation Research Department, General Manager of the Supply Chain Department, General Manager of the Pharmaceutical Division, and Senior Executive Officer in charge of Pharmaceuticals. Since retiring, he has been appointed to committees at the Japan Business Association (JBA), the Japan Agency for Medical Research and Development (AMED), and various government-related bodies. |
| Executive Vice President | Teruhito Yoshioka | Mr. Yoshioka worked at SIIX Corporation for 30 years, engaging in a wide range of duties primarily in sales and procurement. He spent a total of 24 years on overseas assignments in Taiwan, Shanghai, and Germany, where he was involved in sales management and factory operations at local subsidiaries. After serving as Executive Officer in charge of the European Region and General Manager of the Tokyo Sales Department, he joined Renzoku Biologics at its inception. |
| Chief Financial Officer (CFO) | Junichi Kataoka | At SIIX Corporation, Mr. Kataoka demonstrated expertise in general management—including finance, organization, and systems—across multiple locations in Japan, Asia, and Europe for over 20 years, and was deeply involved in the formulation and implementation of business strategies through the promotion of global projects and organizational management. |
| Auditor | Toru Maruyama (COS, Representative Director of SIIX Corporation) |
At Sumitomo Mitsui Banking Corporation, Mr. Maruyama worked in the Planning Department and Corporate Sales Department, and was seconded to the Ministry of Foreign Affairs. At SIIX Corporation, he oversaw the Corporate Planning Department and the General Affairs and Human Resources Department. Starting in March 2025, as Representative Director and Senior Managing Executive Officer of COS, he will lead initiatives to enhance corporate value and improve employee engagement. |
| Executive Officer in Charge of Special Assignments (Business Partnering) |
Fumiaki Yumoto | With over 20 years of research experience in Japan and the San Francisco Bay Area, including serving as a Specially Appointed Associate Professor at the Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization, Dr. Yumoto is well-versed in the fields of structural biology and bioscience. After working to support international business development for biotech startups, he co-founded Renzoku Biologics. |
| Chief Science Advisor | Kohei Tsumoto (Professor, Graduate School of Engineering, The University of Tokyo Professor, Institute of Medical Science, The University of Tokyo) |
Dr. Tsumoto worked at Tohoku University for 10 years, served as a principal investigator at The University of Tokyo for 20 years, and continues in that role to this day. He has consistently led research as an international leader in protein engineering focused on antibodies, various analyses contributing to biopharmaceutical development, and particularly in elucidating and controlling the mechanisms of aggregation and protein-protein interaction analysis. He has extensive experience in industry-academia collaborative research dating back to his time at Tohoku University. He serves on various committees for organizations such as AMED, JST, and JBA. |
| Science Advisor | Hirokazu Sugiyama (Professor, Graduate School of Engineering, The University of Tokyo) |
Dr. Sugiyama researches design and operational support for pharmaceutical manufacturing processes through modeling and simulation. After earning his Ph.D. from ETH Zurich in Switzerland, he was involved in the launch and actual production at Roche’s new biopharmaceutical injectables plant before commencing his current research. |
Contact Us
Contact us with any questions about our services, requests for advice, or quotation requests.
